Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Upgraded at Barclays

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) was upgraded by Barclays to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks.com reports.

Separately, Royal Bank of Canada upgraded Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

Shares of Recordati Industria Chimica e Farmaceutica stock opened at $52.25 on Tuesday. The stock’s 50-day simple moving average is $52.25 and its 200-day simple moving average is $51.87. Recordati Industria Chimica e Farmaceutica has a 52 week low of $52.25 and a 52 week high of $52.25. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.95 and a current ratio of 1.36.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.70 EPS for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The business had revenue of $622.00 million for the quarter.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.